Damien Basille1,2, Nathalie Plouvier3, Charlotte Trouve3, Pierre Duhaut4,5, Claire Andrejak3,4, Vincent Jounieaux3. 1. Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France. basille.damien@chu-amiens.fr. 2. Recif Unit, University Hospital Amiens, Amiens, France. basille.damien@chu-amiens.fr. 3. Respiratory and Intensive Care Unit, University Hospital Amiens, Amiens, 80054, France. 4. Recif Unit, University Hospital Amiens, Amiens, France. 5. Internal Medicine, University Hospital Amiens, Amiens, France.
Abstract
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed or used as self-medication in cases of community-acquired pneumonia (CAP). Nevertheless, the consequences of such medication on the risk of pleuroparenchymal complications are not well known. The aim was to investigate whether exposure to NSAIDs prior to hospital admission among patients suffering from CAP is associated with the development of pleural complications or a lung abscess. METHODS: All consecutive non-immunocompromised patients with CAP and admitted to a university hospital were prospectively included (2-year period). The risk of pleuropulmonary complications was analyzed according to previous exposure to NSAIDs. RESULTS: Of the 221 included patients, 40 (18.1%) had developed a pleuropulmonary complication. NSAIDs intake prior to admission was reported for 24 patients (10.9%) who were younger (50.6 ± 18.5 vs. 66.5 ± 16.4 years; p = 0.001), had less comorbidities (60 vs. 25.1%; p = 0.001), had a longer duration between the first symptoms of CAP and the start of an antibiotic therapy (6.1 ± 7.6 vs. 2.8 ± 3.8 days; p = 0.001), and who had a higher incidence of pleuropulmonary complications (33.3 vs. 16.2%; p = 0.048). In multivariate analyses, two factors were independently associated with the development of pleuroparenchymal complications: NSAIDs intake [Odds Ratio (OR) = 2.57 [1.02-6.64]; p = 0.049] and alcohol abuse (OR = 2.68 [1.27-5.69]; p = 0.01). CONCLUSIONS: Our findings suggest that NSAIDs, often taken by young and healthy patients, may worsen the course of CAP with delayed therapy and a higher rate of pleuropulmonary complications.
PURPOSE: Non-steroidal anti-inflammatory drugs (NSAIDs) are frequently prescribed or used as self-medication in cases of community-acquired pneumonia (CAP). Nevertheless, the consequences of such medication on the risk of pleuroparenchymal complications are not well known. The aim was to investigate whether exposure to NSAIDs prior to hospital admission among patients suffering from CAP is associated with the development of pleural complications or a lung abscess. METHODS: All consecutive non-immunocompromised patients with CAP and admitted to a university hospital were prospectively included (2-year period). The risk of pleuropulmonary complications was analyzed according to previous exposure to NSAIDs. RESULTS: Of the 221 included patients, 40 (18.1%) had developed a pleuropulmonary complication. NSAIDs intake prior to admission was reported for 24 patients (10.9%) who were younger (50.6 ± 18.5 vs. 66.5 ± 16.4 years; p = 0.001), had less comorbidities (60 vs. 25.1%; p = 0.001), had a longer duration between the first symptoms of CAP and the start of an antibiotic therapy (6.1 ± 7.6 vs. 2.8 ± 3.8 days; p = 0.001), and who had a higher incidence of pleuropulmonary complications (33.3 vs. 16.2%; p = 0.048). In multivariate analyses, two factors were independently associated with the development of pleuroparenchymal complications: NSAIDs intake [Odds Ratio (OR) = 2.57 [1.02-6.64]; p = 0.049] and alcohol abuse (OR = 2.68 [1.27-5.69]; p = 0.01). CONCLUSIONS: Our findings suggest that NSAIDs, often taken by young and healthy patients, may worsen the course of CAP with delayed therapy and a higher rate of pleuropulmonary complications.
Authors: M Falguera; J Carratalà; S Bielsa; C García-Vidal; A Ruiz-González; I Chica; F Gudiol; J M Porcel Journal: Eur Respir J Date: 2011-05-12 Impact factor: 16.671
Authors: Ariane Rennó Brogliato; Carlos A Antunes; Renato S Carvalho; Ana Paula T Monteiro; Rodrigo F Tinoco; Marcelo T Bozza; Claudio Canetti; Marc Peters-Golden; Steven L Kunkel; Rosane Vianna-Jorge; Claudia Farias Benjamim Journal: Shock Date: 2012-12 Impact factor: 3.454
Authors: Carrie L Byington; LaShonda Y Spencer; Timothy A Johnson; Andrew T Pavia; Daniel Allen; Edward O Mason; Sheldon Kaplan; Karen C Carroll; Judy A Daly; John C Christenson; Matthew H Samore Journal: Clin Infect Dis Date: 2002-01-03 Impact factor: 9.079
Authors: Mohamed A Elemraid; Matthew F Thomas; Alasdair P Blain; Stephen P Rushton; David A Spencer; Andrew R Gennery; Julia E Clark Journal: Pediatr Pulmonol Date: 2014-04-01
Authors: Victoria C Ziesenitz; Tatjana Welzel; Madelé van Dyk; Patrick Saur; Matthias Gorenflo; Johannes N van den Anker Journal: Paediatr Drugs Date: 2022-09-02 Impact factor: 3.930
Authors: Matthew R Carey; Valerie M Vaughn; Jason Mann; Whitney Townsend; Vineet Chopra; Payal K Patel Journal: J Gen Intern Med Date: 2020-04-08 Impact factor: 5.128
Authors: Andreas Kronenberg; Lukas Bütikofer; Ayodele Odutayo; Kathrin Mühlemann; Bruno R da Costa; Markus Battaglia; Damian N Meli; Peter Frey; Andreas Limacher; Stephan Reichenbach; Peter Jüni Journal: BMJ Date: 2017-11-07
Authors: Zachary A Yetmar; Meltiady Issa; Sadia Munawar; M Caroline Burton; Vincent Pureza; M Rizwan Sohail; Tahir Mehmood Journal: Am J Med Date: 2020-04-25 Impact factor: 4.965